engleski

Biomarkers of treatment response in depression

Biomarkers of treatment response in depression are important since they can be used to predict antidepressant treatment outcome as well as development of side-effects, and therefore to choose the best possible therapy for depression. Studies addressing the pharmacokinetic biomarkers mainly investigated the cytochrome P450 superfamily, and the ATP binding cassette transporter enzymes. Regarding antidepressant treatment response, most studied neurotransmitter biomarkers included components of monoaminergic systems, such as monoamine metabolic enzymes and monoamine transporters, as well as various serotonergic, dopaminergic, adrenergic and glutamatergic receptors. Various neurotrophic and growth factors, inflammatory molecules as as well as stress related biomarkers associated with HPA axis activation, have been also suggested as potential biomarkers of antidepressant response. Accumulating evidence supports structural and functional brain imaging biomarkers as useful tools for providing information regarding antidepressant treatment outcome. In addition, several different electrophysiological and electroencephalography biomarkers show promise for predicting treatment response in depression.

depression ; biomarkers ; treatment response ; neurotransmitters ; neurotrophins ; hypothalamic-pituitary-adrenal axis ; genetic variants ; imaging biomarkers

nije evidentirano